Aim: Etrasimod and ozanimod are selective sphingosine 1-phosphate receptor modulators
targeting the S1P1,4,5, and S1P1,5 receptors, respectively, for the treatment of patients with moderately to severely
active ulcerative colitis (UC). No head-to-head ...